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Objective Hyperkalemia affects up to 10% of hospitalized patients and, if left untreated, can
lead to serious cardiac arrhythmias or death. Although hyperkalemia is frequently encountered
in the emergency department (ED), and is potentially life-threatening, standard of care for the
treatment is poorly defined, with little supporting evidence. The main objectives of this observational study are to define the overall burden of hyperkalemia in the ED setting, describe its
causes, the variability in treatment patterns and characterize the effectiveness and safety of ED
standard of care therapies used in the United States.
Methods This is an observational study evaluating the management of hyperkalemia in the ED.
Two hundred and three patients who presented to the ED with a potassium value ≥5.5 mmol/L
were enrolled in the study at 14 sites across the United States. Patients were treated per standard of care practices at the discretion of the patient’s physician. In patients who received a
treatment for hyperkalemia, blood samples were drawn at pre-specified time points and serum
potassium values were recorded. The change in potassium over 4 hours and the adverse events
after standard of care treatment were analyzed.
Results and Conclusion This article describes the background, rationale, study design, and methodology of the REVEAL-ED (Real World Evidence for Treatment of Hyperkalemia in the Emergency Department) trial, a multicenter, prospective, observational study evaluating contemporary
management of patients admitted to the ED with hyperkalemia.
Keywords Hyperkalemia; Potassium; Electrolyte disturbance

eISSN: 2383-4625

Received: 1 February 2017
Revised: 26 March 2017
Accepted: 28 March 2017
Correspondence to: Zubaid Rafique
Ben Taub General Hospital, Baylor
College of Medicine, 1504 Ben Taub
Loop, Houston, TX 77030, USA
E-mail: zubaidrafique@gmail.com
This study was presented at Society for
Academic Emergency Medicine 2016
meeting, May 10-13, 2016 in New
Orleans, LA; American College of
Emergency Physicians 2016 meeting,
October 15-19, 2016 in Las Vegas, NV,
USA.

How to cite this article:
Rafique Z, Kosiborod M, Clark CL, Singer AJ,
Turner S, Miller J, Char D, Peacock WF. Study
design of Real World Evidence for Treatment
of Hyperkalemia in the Emergency
Department (REVEAL-ED): a multicenter,
prospective, observational study. Clin Exp
Emerg Med 2017;4(3):154-159.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/).

154

Copyright © 2017 The Korean Society of Emergency Medicine

Original Article
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Emergency Department (REVEAL-ED):
a multicenter, prospective,
observational study
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What is already known
Hyperkalemia is frequently encountered in the emergency department and is potentially life threatening. Standard-ofcare treatment for hyperkalemia is limited and poorly defined.
What is new in the current study
This is the first prospective, observational study addressing gaps in knowledge in hyperkalemia treatment. This article
describes the background, rational and methodology of the REVEAL-ED (Real World Evidence for Treatment of Hyperkalemia in the Emergency Department) trial.

INTRODUCTION
Hyperkalemia occurs in up to 10% of hospitalized patients.1-4 Patients with chronic kidney disease and cardiovascular disease, as
well as those who are treated with renin-angiotensin-aldosterone
system inhibitors, are at greater risk of hyperkalemia.5,6 The prevalence of hyperkalemia and related hospitalizations are on the
rise in parallel with increased use of renin-angiotensin-aldosterone system inhibitors and an aging hospitalized patient population.7 Patients are often sent to the emergency department (ED)
due to high potassium levels, and over 800,000 hyperkalemia-related ED visits are estimated to occur annually in the US.8
If left untreated, hyperkalemia can lead to life-threatening cardiac arrhythmias,9-11 and is associated with substantially increased
risk of death.12-14 One study reported in-hospital mortality of patients with hyperkalemia to be as high as 18.1%, while those with
normal potassium to be 3.9%.13 Several other studies have also
shown an increase in the risk of death for serum potassium levels
above 5 mmol/L and a rapid increase in the risk of death as serum
potassium levels exceed 5.5 mmol/L.6,14,15 In particular, a study by
Grodzinsky el al.15 reported that in-hospital mortality was greater
than 15% once the maximum potassium level was above 5.5 mmol/L,
and another study by Einhorn et al.6 reported a 1-day mortality
rate up to 17 times higher for hospitalized patients with potassium levels > 6.0, as compared to < 5.5 mmol/L.
Although no randomized trials on hyperkalemia treatments
and their impact on in-hospital mortality have been conducted,
available observational data suggest that reducing potassium levels in patients with hyperkalemia may lower mortality risk. For
example, an observational cohort study at two medical centers in
Korea found that treatment of patients with hyperkalemia with
common therapies excluding dialysis, improved serum potassium
levels and had a positive association with better survival.16 A separate observational study of hospitalized patients who received
critical care at two tertiary care hospitals in Boston, MA, showed
that a reduction of 1 mmol/L or greater in serum potassium withClin Exp Emerg Med 2017;4(3):154-159

in 48 hours after hospitalization was associated with decreased
mortality risk.17 In addition, a retrospective study of 38,689 consecutive patients with acute myocardial infarction found that inhospital mortality was twice as high among hyperkalemic patients
whose potassium levels remained high compared to patients whose
potassium levels returned to a normal range.15
Although hyperkalemia is frequently encountered in the ED,
and is potentially life-threatening, a standard of care (SOC) for
hyperkalemia treatment is poorly defined. Acute pharmacologic
treatment options for hyperkalemia are limited and their use is
complicated by suboptimal tolerability and safety and uncertain
efficacy. Hemodialysis is effective for the treatment of hyperkalemia, but is invasive and costly, and significant logistical issues
must be overcome in order to initiate this in the ED. In addition,
the emergency management of hyperkalemia is not consistent
across clinicians and institutions in the US.18 A Cochrane review
of emergency management of hyperkalemia suggested that sufficient randomized, controlled trials supporting the use of commonly prescribed therapies are lacking and many of the trials are
methodologically flawed.18 Accordingly, we conducted a multicenter, prospective, observational study to define the overall burden of hyperkalemia in the ED setting, describe its causes, and
variability in treatment patterns and characterize the effectiveness and safety of ED SOC therapies used in the US. We hypothesized that SOC treatment of hyperkalemia is variable and multiple
medications are used in the acute setting. We further hypothesized that all SOC medications are effective in the first four hours
of treatment. To our knowledge, this is the first prospective, rigorously designed observational study directly addressing gaps in
knowledge in the US.

METHODS
Study design
The Real World Evidence for Treatment of Hyperkalemia in the
Emergency Department (REVEAL-ED) is a multicenter, prospec155
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Screening: (1) Standard of care potassium, (2) subject’s chief complaints
upon arrival at emergency department, (3) assess possible cause of hyper
kalemia, and (4) New York Heart Association assessment if history of heart
failure.
Initial intervention/treatment
Blood draws to measure potassium levels
Concomitant medications assessment

Fig. 2. Study design.

Fig. 1. REVEAL-ED (Real World Evidence for Treatment of Hyperkalemia
in the Emergency Department) study sites. Marked areas on the map
represent study sites in the US.

tive, observational study evaluating the management of patients
admitted to the ED with hyperkalemia. The study was approved
by the institutional review board or local ethics committee for
each site and registered at ClinicalTrials.gov (NCT02607085). Each
patient, legally authorized guardian, or a person with legal responsibility for the patient’s health care decisions provided written informed consent prior to participation in any study activities.

Study setting and population
From October 25, 2015 to March 30, 2016, a total of 203 patients
who presented to the ED with a potassium value ≥ 5.5 mmol/L
were enrolled in the study at 14 sites across the US (Fig. 1). Eligible patients were ≥ 18 years of age, provided written informed
consent, and had hyperkalemia confirmed in the ED with a documented potassium ≥ 5.5 mmol/L. Enrollment of patients with a
baseline potassium < 6.0 mmol/L was limited to 50 patients, after
which the entry criteria required a baseline potassium ≥ 6.0 mmol/L.
A point-of-care analyzer was allowed to determine the baseline
potassium level if this was the standard practice at that site. Patients were excluded from the study if, in the opinion of the treating physician, they were unable to perform the tasks associated
with the protocol, they were participating in another clinical study
which could impact the REVEAL-ED study or they had been previously enrolled in this study.

Study protocol
After patients provided written informed consent, their demographics and medical history data, including previous ED visits
and hospital admissions for hyperkalemia, were recorded. Patients
with a prior history of heart failure were classified according to
the New York Heart Association functional classification system.
The baseline study-related whole blood potassium was deter156

mined using a point-of-care device (i-STAT; Abbott Point of Care,
Princeton, NJ, USA), provided by the sponsor, prior to the first intervention for hyperkalemia. If no baseline study-related potassium value was obtained, then the potassium value qualifying the
patient for study entry was considered as the patient’s baseline. If
the SOC potassium value qualifying the patient for the study was
≥ 5.5 mmol/L, but the baseline i-STAT value was < 5.5 mmol/L
then the SOC value was recorded and the patient was allowed to
remain in the study.
In patients who received a treatment for hyperkalemia, studyrelated potassium samples were drawn and analyzed by i-STAT at
0.5, 1, 2, 4, 8, 12, and 24 hours after intervention initiation (Fig.
2). If a patient was transferred from the ED to another hospital
location, then research staff continued to collect study-related iSTAT samples to the extent feasible. If a patient received more
than one intervention for hyperkalemia, then the post-treatment
potassium measurement schedule started from the initiation of
the first intervention, except if a patient received sodium polystyrene sulfonate, then additional study-related potassium samples
were drawn at 1, 2, and 4 hours following initial sodium polystyrene sulfonate administration.
In patients who received no intervention during the initial 4-hour
period, study-related potassium samples were drawn and analyzed by i-STAT at 4, 8, 12, and 24 hours after the SOC potassium
measurement qualifying the patient for study entry. If a patient
was transferred from the ED to another hospital location, then
the site continued to collect study-related i-STAT samples to the
extent feasible.
Patients were treated per SOC practices at the discretion of the
patient’s physician. Any medication administered as part of SOC
practice was provided according to the drug dispensing policy at
each investigational site. No specific treatment algorithms were
prescribed by the study protocol, and no medications were supplied by the sponsor during the study. Available data obtained as
part of ED SOC management were recorded upon ED admission
and up to 24 hours after the initial intervention, or through 24
www.ceemjournal.org
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hours after the potassium measurement that qualified the patient
for entry into the study if no intervention was performed. Available SOC management data that was recorded included physical
examinations, vital signs, fluid intake and urine output, electrocardiograms, clinical laboratory data, and results of chest X-rays.
Data regarding the patient’s chief complaint upon ED admission,
possible cause of the patient’s hyperkalemia, as well as admitting
and discharge diagnoses were recorded. The patient’s overall discharge summary and hospital discharge time were also collected
when possible.
The timing of each hyperkalemia intervention following ED admission as well as the dose and route of administration were recorded. Concomitant medications were collected for the 14 days
before ED admission through ED discharge. If a patient was admitted to another hospital location (i.e., to an in-patient bed), medications administered after ED evaluation was collected for up to seven days or until discharge from the hospital, whichever came first.
Dates and times were recorded for the following (if applicable):
ED admission, hospital admission, intensive care unit admission,
observation unit admission, step down unit admission, regular
floor admission, discharge (from all admissions), dialysis, do not
resuscitate order entry, death, and any other recordable outcome
deemed significant by the investigator.
Recordable outcomes were limited to pulmonary edema, ventricular tachycardia/fibrillation, pulseless electrical activity arrest,
new clinically significant electrocardiogram changes (specifically
including but not limited to severe bradycardia, advanced heart
block, bundle branch block, tachycardia [> 100 bpm]), palpitations,
hypoglycemia, and gastrointestinal-related events (e.g., nausea,
vomiting, diarrhea) and any other event deemed significant by
the investigator. Recordable outcomes requiring positive-pressure
ventilation, central venous access, intubation, chest compressions,
intravenous (IV) vasopressors, IV vasodilators, IV anti-arrhythmics,
and/or emergency dialysis or resulting in death were also collected. These outcomes were recorded from the time of ED admission
through ED discharge. If a patient was admitted to another hospital location, post-ED recordable outcomes were collected for up
to 7 days following admission to that unit or until hospital discharge, if earlier. Recordable outcomes resulting in death while the
patient remained in the hospital were collected for up to 30 days
after ED admission.

Outcome measures
The primary endpoint of the study was the absolute change in
potassium over 4 hours following the initial intervention for hyperkalemia. If a patient did not receive an intervention for hyperkalemia during the ED admission, then the change over 4 hours
Clin Exp Emerg Med 2017;4(3):154-159

following the baseline potassium measurement was used.
Secondary endpoints included the rate of change in potassium
over 4 hours following the initial intervention for hyperkalemia,
change in potassium at other time points (rate, percent and absolute), choice of intervention, timing and details of procedures
relative to ED admission, other outcome events (e.g., hospital and
intensive care unit admissions, cardiac arrhythmias and conduction abnormalities, hemodynamic instability/cardiac arrest, inhospital deaths), as well as safety and tolerability of SOC interventions were also evaluated.

Data analysis
No formal sample size calculation was performed for this study. A
sample size of 200 patients was selected based on clinical judgement and was considered sufficient to adequately characterize
the different interventions in this population. The study populations for analysis include the intent-to-treat and safety populations. The intent-to-treat population included all patients enrolled
in the study with any post-baseline study-related potassium values. The safety population included all patients enrolled in the
study who had any post-baseline follow-up for safety.
Changes in study-related potassium values following an intervention were used to assess efficacy. All analyses were based on
the study-related potassium results obtained using i-STAT. Safety
was evaluated using recordable outcomes, clinical laboratory parameters, vital signs, fluid intake and urine output, physical examination, electrocardiograms, and chest X-rays. The principle of
treatment emergence was employed for the analysis of recordable outcome data. Treatment emergence was defined to be any
event that occurred during the observation period of the study
and was not present at baseline, or one that represents an exacerbation of a condition present at baseline.
Recordable outcomes were classified by the medical dictionary
for regulatory activities (MedDRA). The type, incidence, timing
(onset and duration), relationship to hyperkalemia and to intervention for hyperkalemia, and severity of recordable outcome was
reported for treatment-emergent outcomes. Reasons for withdra
wal due to recordable outcomes were also reported. The incidence
of clinically significant cardiac events (e.g., cardiac arrhythmia,
cardiac arrest, cardiovascular and all-cause death) was calculated. All cardiac events were adjudicated by an independent review
committee prior to database lock using available SOC data for
each case. Descriptive statistics will be presented overall for the
study population, as well as stratified by potassium levels at baseline, and by treatment group. When appropriate, hierarchical multivariable analyses will be performed adjusting for differences in
patient characteristics and hospital site.
157
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Role of the sponsor
The study sponsor participated in developing the study design,
conducted data collection, and will participate in data analyses.
The study investigators and all authors provided critical input for
the study design and methodology, will have free access to the
study data, will lead the analysis and interpretation of the data,
and have sole discretion in the writing of the report and the decision to submit the manuscript for publication.

variability in treatment patterns as well as characterize the effectiveness and safety of ED SOC therapies used to treat hyperkalemia in the US.
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Hyperkalemia is frequently encountered in the ED and can lead to
cardiac arrhythmias or death. Emergency management of hyperkalemia and close monitoring in the hospital setting is often necessary, but SOC for hyperkalemia has not been well characterized.
To our knowledge, this is the first prospective, rigorously designed
observational study directly addressing the gaps in knowledge of
hyperkalemia management in the United States.
A few noteworthy points about our methodology are as follows:
First, our primary end point is to measure the effect of an emergent intervention in the first 4 hours. This time-line was chosen
to evaluate how quickly the SOC intervention is effective, as severe hyperkalemia can be lethal and quick interventions are needed in the emergency setting. Moreover, this time frame made the
study feasible to conduct in the ED setting. Second, we enrolled
only fifty patients with a potassium range ≥ 5.5 mmol/L and < 6.0
mmol/L because we wanted to see the effectiveness of the interventions at higher potassium levels. Lastly, even though this was
an ED based study and we were interested in the effectiveness of
interventions in the first 4 hours, we collected data up to 7 days
after admission, when applicable, so we could evaluate some of
the lasting side effects of the SOC interventions.
This study has several limitations inherent to the nature of an
observational study design. For instance, patients were not randomized to the different interventions since they were treated per
SOC practices at the discretion of the patient’s physician. Also,
the medications administered as part of SOC practice were not
standardized across investigational sites as medications were provided according to the hospital standards at each investigational
site. Hence, we expect to find different dosages of the same medication being used at different sites. The observational design of
the study allows for an accurate description of the current SOC
therapies used to treat hyperkalemia in the US, but the study is
not designed to directly compare the efficacy of these interventions.
In summary, the REVEAL-ED study seeks to define the overall
burden of hyperkalemia in the ED setting and will describe the
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